Endoxifen shows promise in breast cancer

Cancer Discov. 2014 Feb;4(2):OF1. doi: 10.1158/2159-8290.CD-NB2014-002. Epub 2014 Jan 9.

Abstract

In a phase I trial of endoxifen, a metabolite of tamoxifen, multiple patients with estrogen receptor-positive breast cancer that was resistant to treatment with aromatase inhibitors had partial responses or long-lasting stable disease.

Publication types

  • News

MeSH terms

  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Agents, Hormonal / adverse effects
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Female
  • Humans
  • Selective Estrogen Receptor Modulators / administration & dosage
  • Selective Estrogen Receptor Modulators / adverse effects
  • Selective Estrogen Receptor Modulators / therapeutic use*
  • Tamoxifen / administration & dosage
  • Tamoxifen / adverse effects
  • Tamoxifen / analogs & derivatives*
  • Tamoxifen / therapeutic use
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Hormonal
  • Selective Estrogen Receptor Modulators
  • Tamoxifen
  • 4-hydroxy-N-desmethyltamoxifen